Curran Terrie 4
4 · Phathom Pharmaceuticals, Inc. · Filed Jul 17, 2023
Insider Transaction Report
Form 4
Curran Terrie
DirectorPresident and Chief Executive
Transactions
- Disposition to Issuer
Stock Option
2023-07-14−225,000→ 0 totalExercise: $39.11Exp: 2031-01-27→ Common Stock (225,000 underlying) - Disposition to Issuer
Stock Option
2023-07-14−175,000→ 0 totalExercise: $32.20Exp: 2030-06-30→ Common Stock (175,000 underlying) - Award
Common Stock
2023-07-14+200,000→ 389,671 total
Holdings
- 3,579.61(indirect: By 401(k))
Common Stock
Footnotes (3)
- [F1]On July 14, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, options to purchase 400,000 shares of common stock of the Issuer and in exchange issued to the Reporting Person 200,000 restricted stock units, each of which represents a contingent right to receive one share of the Issuer's common stock.
- [F2]Includes 1,381 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2023.
- [F3]Includes 1,223.71 shares acquired under the Phathom Pharmaceuticals, Inc. 401(k) plan.